Open access · CC-BY
via OpenAlex
Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
Ameya S Kulkarni, Sandra Aleksić, David M. Berger, Felipe Sierra, George A. Kuchel, Nir Barzilai
Aging Cell · 2022 · ▲ 132 citations
Abstract
Common chronic diseases represent the greatest driver of rising healthcare costs, as well as declining function, independence, and quality of life. Geroscience-guided approaches seek to delay the onset and progression of multiple chronic conditions by targeting fundamental biological pathways of aging. This approach is more likely to improve overall health and function in old age than treating individual diseases, by addressing aging the largest and mostly ignored risk factor for the leading causes of morbidity in older adults. Nevertheless, challenges in repurposing existing and moving newly discovered interventions from the bench to clinical care have impeded the progress of this potentially transformational paradigm shift. In this article, we propose the creation of a standardized process for evaluating FDA-approved medications for their geroscience potential. Criteria for systematically evaluating the existing literature that spans from animal models to human studies will permit the prioritization of efforts and financial investments for translating geroscience and allow immediate progress on the design of the next Targeting Aging with MEtformin (TAME)-like study involving such candidate gerotherapeutics.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/acel.13596
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Kulkarni, A.S., Aleksić, S., Berger, D.M., Sierra, F., Kuchel, G.A., & Barzilai, N. (2022). Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization. <em>Aging Cell</em>. https://doi.org/10.1111/acel.13596
Vancouver
Kulkarni AS, Aleksić S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization. Aging Cell. 2022. doi:10.1111/acel.13596.
BibTeX
@article{ameya2022Gerosc,
title = {Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization},
author = {Ameya S Kulkarni and Sandra Aleksić and David M. Berger and Felipe Sierra and George A. Kuchel and Nir Barzilai},
journal = {Aging Cell},
year = {2022},
doi = {10.1111/acel.13596},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Medical Research Archives 2024
Open access · CC-BY
An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging
Nature Communications 2023
Open access · CC-BY
Challenges in developing Geroscience trials
Oxidative Medicine and Cellular Longevity 2022
Open access · CC-BY
Pharmacological Approaches to Decelerate Aging: A Promising Path
Oxidative Medicine and Cellular Longevity 2016
Open access · CC-BY
ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age‐Related Diseases
The Journal of Clinical Endocrinology & Metabolism 2020
Preprint · OA
New Horizons: Novel Approaches to Enhance Healthspan Through Targeting Cellular Senescence and Related Aging Mechanisms
Nature Aging 2021
Open access · CC-BY